{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T02:54:04Z","timestamp":1795229644601,"version":"4.10.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA221703"],"award-info":[{"award-number":["P50CA221703"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA221703"],"award-info":[{"award-number":["P50CA221703"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA221703"],"award-info":[{"award-number":["P50CA221703"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA221703"],"award-info":[{"award-number":["P50CA221703"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"Additional funding for this research: Philanthropic contributions to the Melanoma Moon Shots Program of MD Anderson."},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"Additional funding for this research: Philanthropic contributions to the Melanoma Moon Shots Program of MD Anderson and Dr. Miriam and Sheldon G. Adelson Medical Research Foundation."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There is a critical need for effective treatments for leptomeningeal disease (LMD). Here, we report the interim analysis results of an ongoing single-arm, first-in-human phase 1\/1b study of concurrent intrathecal (IT) and intravenous (IV) nivolumab in patients with melanoma and LMD. The primary endpoints are determination of safety and the recommended IT nivolumab dose. The secondary endpoint is overall survival (OS). Patients are treated with IT nivolumab alone in cycle 1 and IV nivolumab is included in subsequent cycles. We treated 25 patients with metastatic melanoma using 5, 10, 20 and 50\u2009mg of IT nivolumab. There were no dose-limiting toxicities at any dose level. The recommended IT dose of nivolumab is 50\u2009mg (with IV nivolumab 240\u2009mg) every 2\u2009weeks. Median OS was 4.9\u2009months, with 44% and 26% OS rates at 26 and 52\u2009weeks, respectively. These initial results suggest that concurrent IT and IV nivolumab is safe and feasible with potential efficacy in patients with melanoma LMD, including in patients who had previously received anti-PD1 therapy. Accrual to the study continues, including in patients with lung cancer. ClinicalTrials.gov registration: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03025256\">NCT03025256<\/jats:ext-link>.<\/jats:p>","DOI":"10.1038\/s41591-022-02170-x","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T11:12:19Z","timestamp":1680606739000},"page":"898-905","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4530-7765","authenticated-orcid":false,"given":"Isabella C.","family":"Glitza Oliva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherise D.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4534-2042","authenticated-orcid":false,"suffix":"Jr","given":"Roland","family":"Bassett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra P.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarin D.","family":"Hennegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Rohlfs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masood","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Dett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Lacey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Haydu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruitao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6876-278X","authenticated-orcid":false,"given":"Rodabe N.","family":"Amaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Diab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4429-7307","authenticated-orcid":false,"given":"Cassian","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-1517","authenticated-orcid":false,"given":"Sapna P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2393-2172","authenticated-orcid":false,"given":"Jennifer L.","family":"McQuade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant M.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1638-3400","authenticated-orcid":false,"given":"Ian E.","family":"McCutcheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar","family":"Tummala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Debnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandita","family":"Guha-Thakurta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3438-7576","authenticated-orcid":false,"given":"Jennifer A.","family":"Wargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C. L.","family":"Carapeto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney W.","family":"Hudgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason T.","family":"Huse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Tetzlaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1942-851X","authenticated-orcid":false,"given":"Hussein A.","family":"Tawbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0977-0912","authenticated-orcid":false,"given":"Michael A.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"2170_CR1","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/pcmr.12538","volume":"29","author":"JV Cohen","year":"2016","unstructured":"Cohen, J. V. et al. Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell Melanoma Res. 29, 627\u2013642 (2016).","journal-title":"Pigment Cell Melanoma Res."},{"key":"2170_CR2","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long, G. V. et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 19, 672\u2013681 (2018).","journal-title":"Lancet Oncol."},{"key":"2170_CR3","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi, H. A. et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N. Engl. J. Med. 379, 722\u2013730 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2170_CR4","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11060-019-03121-2","volume":"142","author":"SD Ferguson","year":"2019","unstructured":"Ferguson, S. D. et al. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). J. Neurooncol. 142, 499\u2013509 (2019).","journal-title":"J. Neurooncol."},{"key":"2170_CR5","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","volume":"22","author":"HA Tawbi","year":"2021","unstructured":"Tawbi, H. A. et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 22, 1692\u20131704 (2021).","journal-title":"Lancet Oncol."},{"key":"2170_CR6","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejca.2020.02.021","volume":"130","author":"S Ugurel","year":"2020","unstructured":"Ugurel, S. et al. Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition \u2013 update 2019. Eur. J. Cancer 130, 126\u2013138 (2020).","journal-title":"Eur. J. Cancer"},{"key":"2170_CR7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/pcmr.12861","volume":"33","author":"IC Glitza","year":"2020","unstructured":"Glitza, I. C. et al. Leptomeningeal disease in melanoma patients: an update to treatment, challenges, and future directions. Pigment Cell Melanoma Res. 33, 527\u2013541 (2020).","journal-title":"Pigment Cell Melanoma Res."},{"key":"2170_CR8","doi-asserted-by":"publisher","first-page":"S265","DOI":"10.4103\/2152-7806.111304","volume":"4","author":"E Le Rhun","year":"2013","unstructured":"Le Rhun, E., Taillibert, S. & Chamberlain, M. C. Carcinomatous meningitis: leptomeningeal metastases in solid tumors. Surg. Neurol. Int. 4, S265\u2013S288 (2013).","journal-title":"Surg. Neurol. Int."},{"key":"2170_CR9","doi-asserted-by":"publisher","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","volume":"28","author":"E Le Rhun","year":"2017","unstructured":"Le Rhun, E. et al. EANO\u2013ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann. Oncol. 28, iv84\u2013iv99 (2017).","journal-title":"Ann. Oncol."},{"key":"2170_CR10","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/2326-6066.CIR-15-0071","volume":"3","author":"IC Glitza","year":"2015","unstructured":"Glitza, I. C. et al. Intrathecal administration of tumor-infiltrating lymphocytes is well tolerated in a patient with leptomeningeal disease from metastatic melanoma: a case report. Cancer Immunol. Res. 3, 1201\u20131206 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"2170_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.21.02229","volume":"40","author":"JD Wolchok","year":"2022","unstructured":"Wolchok, J. D. et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J. Clin. Oncol. 40, 127\u2013137 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2170_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin, K. et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13, 459\u2013465 (2012).","journal-title":"Lancet Oncol."},{"key":"2170_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1200\/JCO.18.00204","volume":"37","author":"HM Kluger","year":"2019","unstructured":"Kluger, H. M. et al. Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a Phase II trial. J. Clin. Oncol. 37, 52\u201360 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2170_CR14","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1345\/aph.1P197","volume":"44","author":"AJ Perissinotti","year":"2010","unstructured":"Perissinotti, A. J. & Reeves, D. J. Role of intrathecal rituximab and trastuzumab in the management of leptomeningeal carcinomatosis. Ann. Pharmacother. 44, 1633\u20131640 (2010).","journal-title":"Ann. Pharmacother."},{"key":"2170_CR15","first-page":"1123","volume":"52","author":"J List","year":"1992","unstructured":"List, J. et al. Cytokine responses to intraventricular injection of interleukin 2 into patients with leptomeningeal carcinomatosis: rapid induction of tumor necrosis factor alpha, interleukin 1 beta, interleukin 6, gamma-interferon, and soluble interleukin 2 receptor (Mr 55,000 protein). Cancer Res. 52, 1123\u20131128 (1992).","journal-title":"Cancer Res."},{"key":"2170_CR16","doi-asserted-by":"publisher","first-page":"e000283","DOI":"10.1136\/esmoopen-2017-000283","volume":"3","author":"IC Glitza","year":"2018","unstructured":"Glitza, I. C. et al. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open 3, e000283 (2018).","journal-title":"ESMO Open"},{"key":"2170_CR17","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41571-022-00686-2","volume":"19","author":"G Claps","year":"2022","unstructured":"Claps, G. et al. The multiple roles of LDH in cancer. Nat. Rev. Clin. Oncol. 19, 749\u2013762 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2170_CR18","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/neuonc\/noaa030","volume":"22","author":"TJ Kaufmann","year":"2020","unstructured":"Kaufmann, T. J. et al. Consensus recommendations for a standardized Brain Tumor Imaging Protocol for clinical trials in brain metastases. Neuro Oncol. 22, 757\u2013772 (2020).","journal-title":"Neuro Oncol."},{"key":"2170_CR19","doi-asserted-by":"publisher","first-page":"e002473","DOI":"10.1136\/jitc-2021-002473","volume":"9","author":"J Naidoo","year":"2021","unstructured":"Naidoo, J. et al. Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. J. Immunother. Cancer 9, e002473 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"2170_CR20","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s41591-020-0918-0","volume":"26","author":"PK Brastianos","year":"2020","unstructured":"Brastianos, P. K. et al. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat. Med. 26, 1280\u20131284 (2020).","journal-title":"Nat. Med."},{"key":"2170_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25859-y","volume":"12","author":"PK Brastianos","year":"2021","unstructured":"Brastianos, P. K. et al. Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. Nat. Commun. 12, 5954 (2021).","journal-title":"Nat. Commun."},{"key":"2170_CR22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11060-011-0592-7","volume":"105","author":"E Le Rhun","year":"2011","unstructured":"Le Rhun, E. et al. Clinicopathological features of breast cancers predict the development of leptomeningeal metastases: a case-control study. J. Neurooncol. 105, 309\u2013315 (2011).","journal-title":"J. Neurooncol."},{"key":"2170_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11060-013-1092-8","volume":"113","author":"E Le Rhun","year":"2013","unstructured":"Le Rhun, E. et al. A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer. J. Neurooncol. 113, 83\u201392 (2013).","journal-title":"J. Neurooncol."},{"key":"2170_CR24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jpba.2018.10.025","volume":"164","author":"D Pluim","year":"2019","unstructured":"Pluim, D. et al. Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid. J. Pharm. Biomed. Anal. 164, 128\u2013134 (2019).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"2170_CR25","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","volume":"395","author":"R Gutzmer","year":"2020","unstructured":"Gutzmer, R. et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 395, 1835\u20131844 (2020).","journal-title":"Lancet"},{"key":"2170_CR26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1023\/A:1006237917632","volume":"42","author":"JC Reijneveld","year":"1999","unstructured":"Reijneveld, J. C., Taphoorn, M. J. & Voest, E. E. A simple mouse model for leptomeningeal metastases and repeated intrathecal therapy. J. Neurooncol. 42, 137\u2013142 (1999).","journal-title":"J. Neurooncol."},{"key":"2170_CR27","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.cell.2017.02.025","volume":"168","author":"A Boire","year":"2017","unstructured":"Boire, A. et al. Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis. Cell 168, 1101\u20131113.e1113 (2017).","journal-title":"Cell"},{"key":"2170_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/1740774507079442","volume":"4","author":"Y Ji","year":"2007","unstructured":"Ji, Y., Li, Y. & Nebiyou Bekele, B. Dose-finding in phase I clinical trials based on toxicity probability intervals. Clin. Trials 4, 235\u2013244 (2007).","journal-title":"Clin. Trials"}],"updated-by":[{"DOI":"10.1038\/s41591-024-02998-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02170-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02170-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02170-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T06:04:51Z","timestamp":1713852291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02170-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["2170"],"URL":"https:\/\/doi.org\/10.1038\/s41591-022-02170-x","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41591-024-02998-5","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]},"assertion":[{"value":"25 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-024-02998-5","URL":"https:\/\/doi.org\/10.1038\/s41591-024-02998-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.C.G.O. has consulted for Bristol Myers Squibb, Array, Novartis and Sintetica; and has been the PI of research funding to MD Anderson by Bristol Myers Squibb, Merck and Pfizer. I.C.G.O. is also funded by the MD Anderson Cancer Melanoma Moonshot and P50CA221703. S.D.F. has previously received research funding from Codiak, and has also been funded by MD Anderson Cancer Center Melanoma Moon Shot Program and P50CA221703. R.B. Jr, A.P.F., I.J., T.D.H., M.R., J.R., M.I., T.D., C.L., N.J., T.R., S.P., S.D., L.H. and R.L. have no competing interests to declare. R.N.A. has received research funding from Bristol Myers Squibb, Novartis, Iovance, Obsidian and Merck. M.K.W. has participated in advisory boards for the following entities: Merck, Pfizer, Bristol Myers Squibb, Regeneron, EMD Serono, Exicure and Castle Biosciences. A.D. has consulted for Bristol Myers Squibb and has been PI of research funding to MD Anderson by Bristol Myers Squibb. C.Y. has consulted for Grey Wolf Therapeutics, Immatics Biotechnologies, RootPath, T-Cypher Bio, GenomeFrontier Therapeutics and Achelois Oncology. S.P.P. has received research funding from Bristol Myers Squibb, Foghorn Therapeutics, InxMed, Novartis, Provectus, Reata Pharmaceuticals and TriSalus Life Sciences; has consulted for Advance Knowledge in Healthcare; and serves on advisory boards for Cardinal Health, Castle Biosciences and TriSalus Life Sciences. J.L.M. has consulted for Merck and has received honorariums from Bristol Myers Squibb and Roche. G.M.F., I.E.M., B.J.O., S.T., M.D. and N.G.-T. have no competing interests to declare. J.A.W. is an inventor on patent WO2020106983A1 submitted by the Board of Regents, The University of Texas System and Institute Gustav Roussy that covers methods and compositions for treating cancer and for predicting a subject\u2019s response to combination checkpoint inhibitor therapy. J.A.W. is inventor on a US patent application (PCT\/US17\/53.717) submitted by the University of Texas MD Anderson Cancer Center that covers methods to enhance ICB responses by modulating the microbiome. J.A.W. is inventor on patent WO2020150429A1 submitted by the Board of Regents, The University of Texas System, that covers methods and compositions for treating immune checkpoint inhibitor-associated colitis in a subject through the administration of fecal matter from a healthy donor to the subject. J.A.W. reports compensation for speaker\u2019s bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, Physician Education Resource, MedImmune and Bristol Myers Squibb; and serves as a consultant and\/or advisory board member for Roche\/Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Merck, Biothera Pharmaceuticals, Microbiome DX and Micronoma. J.A.W. also receives research support from GlaxoSmithKline, Roche\/Genentech, Bristol Myers Squibb and Novartis. E.M.B. has no competing interest to declare. H.A.T. has been a consultant to Bristol Myers Squibb, Genentech, Novartis, Merck, Boxer Capital, Karyopharm, Iovance, Eisai Jazz Pharmaceuticals and Medicenna; and has been the PI of research funding to MD Anderson by Bristol Myers Squibb, Novartis, Merck, Genentech, GlaxoSmithKline, EMD Serono, Eisai, Dragonfly Therapeutics and RAPT Therapeutics. M.A.D. has been a consultant to Roche\/Genentech, Array, Pfizer, Novartis, Bristol Myers Squibb, GlaxoSmithKline, Sanofi-Aventis, Vaccinex, Apexigen, Eisai and ABM Therapeutics; and has been the PI of research grants to MD Anderson by Roche\/Genentech, GlaxoSmithKline, Sanofi-Aventis, Merck, Myriad and Oncothyreon; and is supported by the Dr Miriam and Sheldon G. Adelson Medical Research Foundation, the AIM at Melanoma Foundation, the National Institutes of Health\/National Cancer Institute 1 P50 -02, the American Cancer Society and the Melanoma Research Alliance, Cancer Fighters of Houston, the Anne and John Mendelsohn Chair for Cancer Research and philanthropic contributions to the MD Anderson Cancer Center Melanoma Moon Shot Program.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}